{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:14Z","timestamp":1792686254514,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403761"],"award-info":[{"award-number":["82403761"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114610","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:54:46Z","timestamp":1744289686000},"page":"114610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TRx0237 induces apoptosis and enhances anti-PD-1 immunotherapeutic efficacy in anaplastic thyroid Cancer"],"prefix":"10.1016","volume":"155","author":[{"given":"Qingyang","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanqing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114610_bb0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.intimp.2025.114610_bb0010","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2025.114610_bb0015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.114610_bb0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14737140.2022.2139680","article-title":"Evaluating new treatments for anaplastic thyroid cancer","volume":"22","author":"Coca-Pelaz","year":"2022","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.intimp.2025.114610_bb0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association guidelines for Management of Patients with anaplastic thyroid Cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.intimp.2025.114610_bb0030","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","article-title":"Dabrafenib and Trametinib therapy for advanced anaplastic thyroid Cancer - real-world outcomes from UK Centres","volume":"35","author":"Lorimer","year":"2023","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"key":"10.1016\/j.intimp.2025.114610_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114610_bb0040","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"Wagle","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114610_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ecl.2021.11.020","article-title":"Anaplastic thyroid Cancer: new horizons and challenges","volume":"51","author":"Maniakas","year":"2022","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.intimp.2025.114610_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.114610_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","article-title":"Machine and deep learning approaches for cancer drug repurposing","volume":"68","author":"Issa","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2025.114610_bb0060","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1158\/2159-8290.CD-21-0612","article-title":"Can drug repurposing accelerate precision oncology?","volume":"12","author":"Schipper","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.114610_bb0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14656566.2020.1719066","article-title":"An evaluation of hydromethylthionine as a treatment option for Alzheimer\u2019s disease","volume":"21","author":"Hashweh","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114610_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-191173","article-title":"Concentration-dependent activity of Hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia","volume":"75","author":"Shiells","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.intimp.2025.114610_bb0075","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14283\/jpad.2022.63","article-title":"Oral tau aggregation inhibitor for Alzheimer\u2019s disease: design, Progress and basis for selection of the 16 mg\/day dose in a phase 3, randomized, placebo-controlled trial of Hydromethylthionine Mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.intimp.2025.114610_bb0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.intimp.2025.114610_bb0085","first-page":"13","article-title":"Tau regulates glioblastoma progression, 3D cell organization, growth and migration via the PI3K-AKT Axis","author":"Pagano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.114610_bb0090","doi-asserted-by":"crossref","first-page":"101087","DOI":"10.18632\/oncotarget.19686","article-title":"Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel\/carboplatin neoadjuvant chemotherapy","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.114610_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109249","article-title":"Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response","volume":"118","author":"Lin","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114610_bb0100","series-title":"Ho PC","first-page":"9","author":"Di Conza","year":"2020"},{"key":"10.1016\/j.intimp.2025.114610_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823157","article-title":"The unfolded protein response at the tumor-immune Interface","volume":"13","author":"Zanetti","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114610_bb0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2025.114610_bb0115","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41598-018-20541-8","article-title":"Ormeloxifene-induced unfolded protein response contributes to autophagy-associated apoptosis via disruption of Akt\/mTOR and activation of JNK","volume":"8","author":"Bhattacharjee","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114610_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1566524016666160523143937","article-title":"The role of the PERK\/eIF2alpha\/ATF4\/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress","volume":"16","author":"Rozpedek","year":"2016","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.intimp.2025.114610_bb0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13046-018-0889-x","article-title":"Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1\/JNK, PERK\/CHOP and TRIB3","volume":"37","author":"Ma","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.114610_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115036","article-title":"Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies","volume":"165","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114610_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2025.114610_bb0140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1152\/physrev.00026.2013","article-title":"Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release","volume":"94","author":"Zorov","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.intimp.2025.114610_bb0145","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cell.2015.10.001","article-title":"Mitochondrial ROS signaling in organismal homeostasis","volume":"163","author":"Shadel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.114610_bb0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in Cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.114610_bb0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.semcancer.2018.08.010","article-title":"Oxidative stress-modulating drugs have preferential anticancer effects - involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration","volume":"58","author":"Tang","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2025.114610_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154655","article-title":"Plumbagin induces the apoptosis of drug-resistant oral cancer in vitro and in vivo through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction","volume":"111","author":"Lin","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.114610_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115404","article-title":"The organic arsenical-derived thioredoxin and glutathione system inhibitor ACZ2 induces apoptosis and autophagy in gastric cancer via ROS-dependent ER stress","volume":"208","author":"Li","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114610_bb0170","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.114610_bb0175","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/nm.4238","article-title":"Patient-derived induced pluripotent stem cells in cancer research and precision oncology","volume":"22","author":"Papapetrou","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.114610_bb0180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00109-020-01990-z","article-title":"Cancer research using organoid technology","volume":"99","author":"Kretzschmar","year":"2021","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.intimp.2025.114610_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107668","article-title":"Tumor organoid models in precision medicine and investigating cancer-stromal interactions","volume":"218","author":"Xu","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114610_bb0190","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019101654","article-title":"Xenograft and organoid model systems in cancer research","volume":"38","author":"Bleijs","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2025.114610_bb0195","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/clinem\/dgab020","article-title":"Organoid cultures derived from patients with papillary thyroid Cancer","volume":"106","author":"Chen","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2025.114610_bb0200","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/jgh.15930","article-title":"Patient-derived cancer organoids for drug screening: basic technology and clinical application","volume":"37","author":"Ren","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.114610_bb0205","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic Cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.114610_bb0210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for Cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114610_bb0215","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/s41598-021-87575-3","article-title":"Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer","volume":"11","author":"Shimada","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114610_bb0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/his.13230","article-title":"CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy","volume":"71","author":"Zwaenepoel","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.intimp.2025.114610_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107458","article-title":"The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells","volume":"209","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.114610_bb0230","doi-asserted-by":"crossref","first-page":"1501613","DOI":"10.3389\/fimmu.2024.1501613","article-title":"Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials","volume":"15","author":"Ren","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114610_bb0235","first-page":"41","article-title":"The cytotoxic effect of memantine and its effect on cytoskeletal proteins expression in metastatic breast cancer cell line","volume":"20","author":"Seifabadi","year":"2017","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.intimp.2025.114610_bb0240","doi-asserted-by":"crossref","unstructured":"Sekino Y, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, et al. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer. Urol. Oncol. 2020;38:795 e791\u2013795 e798.","DOI":"10.1016\/j.urolonc.2020.04.032"},{"key":"10.1016\/j.intimp.2025.114610_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111785","article-title":"Therapeutic contribution of tau-binding Thiazoloflavonoid hybrid derivatives against glioblastoma using pharmacological approach in 3D spheroids","volume":"25","author":"Relave","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114610_bb0250","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ijbiomac.2018.09.118","article-title":"Silica nanoparticles induce conformational changes of tau protein and oxidative stress and apoptosis in neuroblastoma cell line","volume":"124","author":"Roshanfekrnahzomi","year":"2019","journal-title":"Int. J. Biol. Macromol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:31:15Z","timestamp":1778052675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925006009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":50,"alternative-id":["S1567576925006009"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114610","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRx0237 induces apoptosis and enhances anti-PD-1 immunotherapeutic efficacy in anaplastic thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114610"}}